Principal Investigator: Constantine G. Lyketsos, M.D., M.H.S. [ Bio ]|
The goal of this study is to determine whether Citalopram is a more effective treatment for agitation in patients with Alzheimer’s disease than placebo. Participants are randomized to drug or placebo and followed for 9 weeks. Six sites throughout the U.S. are participating in the study. Approximately 20 patients will be enrolled at Johns Hopkins.
For more information, contact Julie Pedroso at email@example.com or 410-550-9054.